Skip to main content
| News

University of Basel investigating active substances against the coronavirus

09.03.2020

The University of Basel is using computer-aided methods in its efforts to find an active substance to fight the coronavirus. A total of just under 700 million substances have been tested on a virtual basis. This has allowed interesting substances to be identified already.

Research (Img: FreeImages.com)

The search for an active substance effective against the coronavirus is being advanced by a Computational Pharmacy research group at the Department of Pharmaceutical Sciences of the University of Basel, as detailed in a press release. The research group is being headed up by Markus Lill and has conducted virtual screening, as part of which more than 680 million substances have already been tested on a virtual basis.

The tests are focused on an important enzyme of the coronavirus, namely the central protease. If the virus’s critical enzyme can be inhibited, this can prevent it from further multiplying. A number of “interesting substances” have already been identified. “Even if the complete development of a drug to fight this particular coronavirus is likely to exceed the duration of the current epidemic, it is important to develop drugs for future coronaviruses”, Lill explains in the press release.

The Basel-based research group’s recent work should serve as a foundation. This is also illustrated by the fact that the research group has taken the decision to immediately make “the test results publicly available in the form of an open-source preprint”. The aim of the Basel researchers is therefore to allow other research groups to make use of their proposals and test potential drug candidates themselves. This approach is rooted in the current emergency situation, given that it is otherwise customary for interesting substances to be first experimentally tested together with other research groups before the results are patented and published, the press release states.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

KetoSwiss secures capital increase of 4 million dollars

KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based startup develops products to alleviate neurological...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Escientia Switzerland becomes Primopus

The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
1 2 3 35

Do you have a question? We'd like to hear from you.